NEW YORK, Feb. 17 (GenomeWeb News) - Ciphergen Biosystems today reported increased revenues, along with stable losses and R&D expenses, for the last quarter of 2003.
Revenues for the quarter were $15.2 million, up from $13.6 million during the same period in 2002.
R&D expenses totaled $6.1 million, almost the same as during the year-ago period.
The company's net loss for the quarter stayed stable at $6.7 million, or $.23 per share, compared to $6.7 million, or $.25 per share, during the same quarter a year ago.
As of Dec. 31, Ciphergen had cash and investments of $47.3 million.